Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02994342
Other study ID # Z7213M02
Secondary ID
Status Completed
Phase N/A
First received December 1, 2016
Last updated June 27, 2017
Start date October 2012
Est. completion date October 2015

Study information

Verified date June 2017
Source Zambon SpA
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evaluation of ZP-025 vaginal gel in terms of efficacy and safety in the treatment of vaginal dryness in post-menopausal women with vaginal atrophy in comparison to a group of non-treated post-menopausal women with vaginal atrophy after 56 consecutive days and at 4-week follow-up only for women applying ZP-025 vaginal gel.


Description:

Evaluation of ZP-025 vaginal gel in terms of efficacy, tolerability and safety in the treatment of vaginal dryness in post-menopausal women with vaginal atrophy in comparison to a group of non-treated post-menopausal women with vaginal atrophy for 56 consecutive days.

This trial will be conducted in compliance with last version of Declaration of Helsinki, with GCP as applicable to investigations with IMD, with the applicable regulatory requirements and with CRO and Sponsor's SOPs.

This is a multi-centre, national, randomized, controlled vs. no-treatment, open label study The study will take place in 6 centers of menopause at public Hospitals/Universities. An ancillary study will be carried on for subjects randomized to ZP-025 group with a follow-up visit at 4 weeks


Recruitment information / eligibility

Status Completed
Enrollment 121
Est. completion date October 2015
Est. primary completion date December 2014
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- caucasian women <70 years, in physiological postmenopausal status for at least 2 years;

- women with signs and symptoms of vaginal atrophy (i. e. vaginal discomfort, itching, dyspareunia, dryness);

- signed informed consent; willing and able to comply with study procedures

Exclusion Criteria:

- childbearing potential women;

- ascertained or presumptive hypersensitivity to the formulation ingredients;

- therapy with systemic or vaginal oestrogens within 6 months from the inclusion;

- current urinary or vaginal infection (cultural positive result to vaginal or urines microbiological swab in the 7 days preceding inclusion);

- previous episodes of vaginal bleeding or spotting in the last 6 months;

- vaginal prolapse and any other disease that could interfere with the study conduction and participation

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Vaginal gel, Medical Device Class 2A
Application twice a day of vaginal gel for 56 consecutive days

Locations

Country Name City State
Italy Ospedale San Giovanni di Dio Cagliari
Italy Policlinico Careggi Firenze
Italy Clinica Macedonio Melloni Milano
Italy Policlinico di Modena Modena
Italy Policlinico Federico II Napoli
Italy Policlinico San Matteo Pavia

Sponsors (1)

Lead Sponsor Collaborator
Zambon SpA

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in subjective symptoms of total score related to vaginal discomfort Change in subjective symptoms of total score related to vaginal discomfort (vaginal dryness, vaginal and/or vulvar irritation/itching, vaginal soreness, dysuria, and dyspareunia and vaginal bleeding associated with sexual activity) has been recorded on daily diary by subject from baseline to day 56, evaluated using a subjective evaluation scale (VRS at four items: 0= absent, 1= mild, 2=moderate, 3=severe). Each item is summed up to get to a total symptoms score. 56 days
Secondary change of vaginal health index change of vaginal health index calculated on the basis of vaginal moistness, vaginal fluid volume, vaginal elasticity, vaginal mucosa, and vaginal pH on a scale ranging from 1 (poorest) to 5 (best) from baseline (day 0), to day 56 recorded by investigator 56 days
Secondary change of maturation index change of maturation index: parabasal, intermediate and superficial cells from baseline (day 0) to day 56 56 days
Secondary change of Female Sexual Function Index change of Female Sexual Function Index (FSFI) from baseline to day 56 in women with at least one sexual intercourse in the treatment period recorded by subject 56 days
Secondary change in each subjective symptom score related to vaginal discomfort change in each symptom score from baseline to end of study recorded on daily diary by subject(vaginal dryness, vaginal and/or vulvar irritation/itching, vaginal soreness, dysuria, and dyspareunia and vaginal bleeding associated with sexual activity) has been recorded on daily diary by subject from baseline to day 56, evaluated using a subjective evaluation scale (VRS at four items: 0= absent, 1= mild, 2=moderate, 3=severe). 56 days
Secondary local tolerability and incidence of adverse events local tolerability registered daily by subject in the subject's diary during the application; period and by the investigator from baseline to day 56; AEs registered over all study period (first patient in - last patient out) - In particular the following assessments will be done: vital signs during all visits. transvaginal ecography to exclude any possible endometrial disease or endometrial thickness variation at the screening visit and at the end of the study, clinical evaluation by the investigator at all visits. 56 days
Secondary change of Female Sexual Distress Scale-Revised change of Female Sexual Distress Scale-Revised (FSDS-R revised 2005) from baseline (Day 0) to day 28 and to the end of the study in women with at least one sexual intercourse in the treatment period recorded by subject 56 days
Secondary change of cariopicnotic index (CPI), change of cariopicnotic index (CPI), as a correlation of superficial cells with picnotic nuclear and general amount of cells ratio, expressed in percentage from baseline (day 0), to day 56 56 days
See also
  Status Clinical Trial Phase
Not yet recruiting NCT01170195 - Effectiveness of Licorice Extract Dietary Supplement on the Treatment of Postmenopausal Symptoms Phase 1/Phase 2
Withdrawn NCT03666819 - Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy Phase 2
Completed NCT02937805 - Effects of a Moisturizing Cream on Vaginal and Vulvar Mucous Membranes N/A
Recruiting NCT05913479 - Evaluation of the Efficacy and Safety of Mucogye® Gel as a Moisturizer N/A
Completed NCT03307044 - Fractional CO2 Laser Therapy for Survivors of Breast Malignancies N/A
Recruiting NCT03714581 - Laser Therapy Following Radiotherapy for Gynecological Cancer N/A
Completed NCT01948583 - Humectant Activity of a New Formulation of Gynomunal® Vaginalgel Phase 4
Completed NCT03178825 - Hybrid Fractional Laser for Symptoms of Genitourinary Syndrome of Menopause N/A
Completed NCT03372720 - Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors N/A
Not yet recruiting NCT06282614 - Performance and Safety of MUCOGYNE® Ovule as a Moisturizer N/A
Completed NCT02176083 - Reproductive Health Survivorship Care Plan Pilot N/A
Completed NCT04908124 - A Clinical Investigation Into the Effectiveness and Safety of Five Water Based Personal Lubricants. Phase 3
Not yet recruiting NCT05156502 - To Assess Signs and Symptoms in Women Affected by GSM After One Cycle of Pixel CO2-Alma Fractionated Laser N/A
Completed NCT02638337 - Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause Phase 3
Not yet recruiting NCT02987647 - Perception of Efficacy, Safety and Tolerability of Three Non-hormonal Intravaginal Gels and Hormone Cream Phase 4
Not yet recruiting NCT03782961 - Evaluation of Viscosity of a Vaginal Moisturizer Phase 4
Completed NCT01697345 - Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy Phase 0
Withdrawn NCT01724242 - Vaginal DHEA for Women After Breast Cancer Phase 2/Phase 3
Completed NCT02269826 - Efficacy and Safety of Non-hormonal Vaginal Preparations in Treating Vaginal Dryness N/A
Completed NCT05644444 - Effectiveness and Safety of a Water-based and a Silicone-based Personal Lubricants With Sensory Action N/A